Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
HARMONi-7
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
1 other identifier
interventional
780
16 countries
202
Brief Summary
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 nonsmall-cell-lung-cancer
Started Feb 2025
202 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 3, 2025
CompletedFirst Posted
Study publicly available on registry
January 10, 2025
CompletedStudy Start
First participant enrolled
February 27, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2029
February 24, 2026
February 1, 2026
3.1 years
January 3, 2025
February 20, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Overall Survival (OS)
Up to approximately 36 months
Progression free survival (PFS)
Up to approximately 36 months
Secondary Outcomes (4)
Objective response rate (ORR)
Up to approximately 36 months
Disease control rate ( DCR)
Up to approximately 36 months
Duration of response (DoR)
Up to approximately 36 months
Adverse Events (AE): incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results
[Time Frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE related to ivonescimab/pembrolizumab ) after the last dose of study treatment or initiation of other anticancer therapy, whichever occurs first, Up to approximately 24 months.
Study Arms (2)
Arm A - Ivonescimab
EXPERIMENTALSubject will receive ivonescimab as an IV injection
Arm B - Pembrolizumab
ACTIVE COMPARATORSubject will receive pembrolizumab as an IV injection
Interventions
Subject will receive ivonescimab as an IV injection
Subject will receive Pembrolizumab as an IV injection
Eligibility Criteria
You may qualify if:
- Age ≥ 18 years old at the time of enrollment
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
- Expected life expectancy ≥ 3 months
- Metastatic (Stage IV) NSCLC
- Histologically or cytologically confirmed squamous or non-squamous NSCLC
- Tumor demonstrates high PD-L1 expression ( TPS\>50%) based on a 22C3 immunohistochemistry ( IHC) clinical assay approved / cleared by local health authorities.
- At least one measurable noncerebral lesion according to RECIST 1.1
- No prior systemic treatment for metastatic NSCLC.
You may not qualify if:
- Histologic or cytopathologic evidence of the presence of small cell lung carcinoma for which first-line approved therapies are indicated. For patients with non-squamous histology, actionable driver mutation testing results are required before randomization.
- Has received any prior therapy for NSCLC in the metastatic setting.
- Concurrent enrollment in another clinical study, unless patient is enrolled in a non-interventional clinical study or is completing survival follow -up.
- Known actionable genomic alterations for which first-line approved therapies are indicated
- Symptomatic CNS metastases, CNS metastasis ≥ 1.5 cm, CNS radiation within 7 days prior to randomization, potential need for CNS radiation within the first cycle, or leptomeningeal disease
- Other prior malignancy (including previously treated NSCLC) unless the patient has undergone curative therapy with no evidence of recurrence of the disease for 3 years prior to randomization
- Active autoimmune or lung disease requiring systemic therapy
- Has pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE version 5
- Severe infection within 4 weeks prior to randomization
- Major surgical procedures or serious trauma within 4 weeks prior to randomization
- History of noninfectious pneumonia requiring systemic corticosteroids, or current interstitial lung disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (202)
Clinical Study Site
Chandler, Arizona, 85224, United States
Clinical Study Site
Phoenix, Arizona, 85006, United States
Clinical Study Site
Hot Springs, Arkansas, 71913, United States
Clinical Study Site
Cerritos, California, 90703, United States
Clinical Study Site
Glendale, California, 91204, United States
Clinical Study Site
Irvine, California, 92612, United States
Clinical Study Site
Los Angeles, California, 90067, United States
Clinical Study Site
Mountain View, California, 94040, United States
Clinical Study Site
Murrieta, California, 92562, United States
Clinical Study Site
Newport Beach, California, 92663, United States
Clinical Study Site
Roseville, California, 95661, United States
Clinical Study Site
Sacramento, California, 95816, United States
Clinical Study Site
San Diego, California, 92123, United States
Clinical Study Site
San Francisco, California, 94115, United States
Clinical Study Site
Santa Ana, California, 92705, United States
Clinical Study Site
Whittier, California, 90602, United States
Clinical Study Site
Aurora, Colorado, 80045, United States
Clinical Study Site
Grand Junction, Colorado, 81505, United States
Clinical Study Site
Greeley, Colorado, 80631, United States
Clinical Study Site
Lone Tree, Colorado, 80124, United States
Clinical Study Site
Loveland, Colorado, 80538, United States
Clinical Study Site
Fort Lauderdale, Florida, 33317, United States
Clinical Study Site
Hialeah, Florida, 33013, United States
Clinical Study Site
Jacksonville, Florida, 32256, United States
Clinical Study Site
Miami, Florida, 33155, United States
Clinical Study Site
North Venice, Florida, 34275, United States
Clinical Study Site
Orlando, Florida, 32822, United States
Clinical Study Site
Pensacola, Florida, 32504, United States
Clinical Study Site
Plantation, Florida, 33322, United States
Clinical Study Site
Plantation, Florida, 33323, United States
Clinical Study Site
Tallahassee, Florida, 32308, United States
Clinical Study Site
Tamarac, Florida, 33321, United States
Clinical Study Site
West Palm Beach, Florida, 33401, United States
Clinical Study Site
Atlanta, Georgia, 30318, United States
Clinical Study Site
Macon, Georgia, 30318, United States
Clinical Study Site
Macon, Georgia, 31210, United States
Clinical Study Site
Carterville, Illinois, 62918, United States
Clinical Study Site
Indianapolis, Indiana, 46237, United States
Clinical Study Site
Waukee, Iowa, 50263, United States
Clinical Study Site
Lexington, Kentucky, 40503, United States
Clinical Study Site
Covington, Louisiana, 70433, United States
Clinical Study Site
Baltimore, Maryland, 21229, United States
Clinical Study Site
Boston, Massachusetts, 02215, United States
Clinical Study Site
Milton, Massachusetts, 02186, United States
Clinical Study Site
Worcester, Massachusetts, 01655, United States
Clinical Study Sites
Detroit, Michigan, 48202, United States
Clinical Study Site
Detroit, Michigan, 48202, United States
Clinical Study Site
Lansing, Michigan, 48910, United States
Clinical Study Site
Minneapolis, Minnesota, 55455, United States
Clinical Study Site
Saint Louis Park, Minnesota, 55426, United States
Clinical Study Site
Saint Paul, Minnesota, 55101, United States
Clinical Study Site
Hattiesburg, Mississippi, 39401, United States
Clinical Study Site
Kansas City, Missouri, 64132, United States
Clinical Study Site
St Louis, Missouri, 63128, United States
Clinical Study Site
Lebanon, New Hampshire, 03756, United States
Clinical Study Site
Basking Ridge, New Jersey, 07920, United States
Clinical Study Site
Middletown, New Jersey, 07748, United States
Clinical Study Site
Montvale, New Jersey, 07645, United States
Clinical Study Site
Mullica Hill, New Jersey, 08062, United States
Clinical Study Site
New Brunswick, New Jersey, 08901, United States
Clinical Study Site
Glen Falls, New York, 12801, United States
Clinical Study Site
Harrison, New York, 10604, United States
Clinical Study Site
New York, New York, 10065, United States
Clinical Study Site
Syracuse, New York, 13210, United States
Clinical Study Site
Uniondale, New York, 11553, United States
Clinical Study Site
Chapel Hill, North Carolina, 27592, United States
Clinical Study Site
Columbus, Ohio, 43219, United States
Clinical Study Sites
Lebanon, Ohio, 45036, United States
Clinical Study Site
Oklahoma City, Oklahoma, 73102, United States
Clinical Study Site
Eugene, Oregon, 97401, United States
Clinical Study Site
Portland, Oregon, 97239, United States
Clinical Study Site
Philadelphia, Pennsylvania, 19111, United States
Clinical Study Site
Pittsburgh, Pennsylvania, 15232, United States
Clinical Study Site
Nashville, Tennessee, 37235, United States
Clinical Study Site
Abilene, Texas, 79601, United States
Clinical Study Site
Austin, Texas, 78745, United States
Clinical Study Site
Dallas, Texas, 75246, United States
Clinical Study Site
Forth Worth, Texas, 76104, United States
Clinical Study Site
Houston, Texas, 77030, United States
Clinical Study Site
Tyler, Texas, 75708, United States
Clinical Study Site
Webster, Texas, 77598, United States
Clinical Study Site
Salt Lake City, Utah, 84106, United States
Clinical Study Site
Blacksburg, Virginia, 24060, United States
Clinical Study Site
Charlottesville, Virginia, 22908, United States
Clinical Study Site
Fairfax, Virginia, 22031, United States
Clinical Study Site
Richmond, Virginia, 23229, United States
Clinical Study Site
Richmond, Virginia, 23298, United States
Clinical Study Site
Seattle, Washington, 98109, United States
Clinical Study Site
Vancouver, Washington, 98684, United States
Clinical Study Site
Edmonton, Alberta, T6G 1Z2, Canada
Clinical Study Site
London, Ontario, N6A 5W9, Canada
Clinical Study Site
Montreal, Quebec, H3T 1E2, Canada
Clinical Study Site
Montreal, H3T 1E2, Canada
Clinical Study Site
Fuzhou, Fujian, China
Clinical Study Site
Guangzhou, Guangdong, China
Clinical Study Site
Haikou, Hainan, China
Clinical Study Site
Harbin, Heilongjiang, 150081, China
Clinical Site Study
Changzhou, Jiangsu, China
Clinical Study Site
Ganzhou, Jiangxi, China
Clinical Study Site
Nanchang, Jiangxi, China
Clinical Study Site
Tai’an, Shandong, China
Clinical Study Site
Weifang, Shandong, China
Clinical Study Site
Shanghai, Shanghai Municipality, China
Clinical Study Site
Kunming, Yunnan, China
Clinical Study Site
Hangzhou, Zhejiang, China
Clinical Study Site
Taizhou, Zhejiang, China
Clinical Site Study
Wenzhou, Zhejiang, China
Clinical Study Site
Changchun, China
Clinical Study Site
Guangzhou, China
Clinical Study Site
Xi'an, China
Clinical Study Site
Nantes, Pays de Loire, 44277, France
Clinical Study Site
Brest, 29200, France
Clinical Study Site
Créteil, 94010, France
Clinical Study Site
Lyon, 69008, France
Clinical Study Site
Marseille, 13000, France
Clinical Study Site
Paris, 75020, France
Clinical Study Site
Rennes, 35033, France
Clinical Study Site
Villejuif, 94800, France
Clinical Study Site
Chemnitz, 91116, Germany
Clinical Study Site
Gauting, 82131, Germany
Clinical Study Site
Giesen, 35392, Germany
Clinical Study Site
Karlsruhe, 76137, Germany
Clinical Study Site
Minden, 32429, Germany
Clinical Study Site
Moers, 47441, Germany
Clinical Study Site
Möser, 47441, Germany
Clinical Study Site
Athens, 15562, Greece
Clinical Study Site
Rio, 26504, Greece
Clinical Study Site
Thessaloniki, 546 22, Greece
Clinical Study Site
Budapest, 01121, Hungary
Clinical Study Site
Kecskemét, 6000, Hungary
Clinical Study Site
Bari, 70124, Italy
Clinical Study Site
Milan, 20037, Italy
Clinical Study Site
Milan, 20141, Italy
Clinical Study Site
Orbassano, 10043, Italy
Clinical Study Site
Parma, 43126, Italy
Clinical Study Site
Roma, 00144, Italy
Clinical Study Site
Asahikawa, Hokkaido, 078-8510, Japan
Clinical Study Site
Nishinomiya, Hyōgo, 663-8501, Japan
Clinical Study Site
Matsusaka, Mie-ken, 515-8544, Japan
Clinical Study Site
Sendai, Miyagi, 980-8574, Japan
Clinical Study Site
Omura-shi, Nagasaki, 856-8562, Japan
Clinical Study Site
Hirakata, Osaka, 573-1191, Japan
Clinical Study Site
Osaka, Osaka, 541-8567, Japan
Clinical Study Site
Hidaka, Saitama, 350-1298, Japan
Clinical Study Site
Shimotsuke, Tochigi, 329-0498, Japan
Clinical Study Site
Bunkyō-Ku, Tokyo, 113-8677, Japan
Clinical Study Site
Koto-Ku, Tokyo, 135-8550, Japan
Clinical Study Site
Wakayama, Wakayama, 641-8510, Japan
Clinical Study Site
Kanazawa, 920-8641, Japan
Clinical Study Site
Kumamoto, 861-4193, Japan
Clinical Study Site
Kurume, 830-0011, Japan
Clinical Study Site
Nagoya, 460-0001, Japan
Clinical Study Site
Okayama, 700-8558, Japan
Clinical Study Site
Sakai, 591-8555, Japan
Clinical Study Site
Tokyo, 104-0045, Japan
Clinical Study Site
Guadalajara, 44670, Mexico
Clinical Study Site
Mexico City, 06700, Mexico
Clinical Study Site
Monterrey, 64710, Mexico
Clinical Study Site
Veracruz, 91900, Mexico
Clinical Study Site
Gdansk, 80214, Poland
Clinical Study Site
Lodz, 93338, Poland
Clinical Study Site
Lublin, 20064, Poland
Clinical Study Site
Poznan, 60-693, Poland
Clinical Study Site
Skorzewo, 60185, Poland
Clinical Study Site
Braga, 4710-243, Portugal
Clinical Study Site
Coimbra, 3020-479, Portugal
Clinical Study Site
Faro, 8000-386, Portugal
Clinical Study Site
Porto, 4099-001, Portugal
Clinical Study Site
Suceagu, Cluj, 407062, Romania
Clinical Study Site
Baia Mare, 430031, Romania
Clinical Study Site
Bucharest, 22328, Romania
Clinical Study Site
Cluj-Napoca, 407062, Romania
Clinical Study Site
Cluj-Napoca, 407280, Romania
Clinical Study Site
Craiova, 200542, Romania
Clinical Study Site
Iași, 700106, Romania
Clinical Study Site
Ovidiu, 905900, Romania
Clinical Study Site
Timișoara, 300166, Romania
Clinical Study Site
Belgrade, 11040, Serbia
Clinical Study Site
Belgrade, 11080, Serbia
Clinical Study Site
Kragujevac, 34000, Serbia
Clinical Study Site
Novi Sad, 21204, Serbia
Clinical Study Site
Badajoz, 06080, Spain
Clinical Study Site
Badalona, 08916, Spain
Clinical Study Site
Barcelona, 08003, Spain
Clinical Study Site
Girona, 17007, Spain
Clinical Study Site
Las Palmas, 35016, Spain
Clinical Study Site
Lugo, 27002, Spain
Clinical Study Site
Madrid, 28040, Spain
Clinical Study Site
Málaga, 29011, Spain
Clinical Study Site
Seville, 41014, Spain
Clinical Study Site
Valencia, 46026, Spain
Clinical Study Site
Zaragoza, 50009, Spain
Clinical Study Site
Adana, 01140, Turkey (Türkiye)
Clinical Study Site
Ankara, 06520, Turkey (Türkiye)
Clinical Study Site
Antalya, 07059, Turkey (Türkiye)
Clinical Study Site
Diyarbakır, 21280, Turkey (Türkiye)
Clinical Study Site
Gaziantep, 27060, Turkey (Türkiye)
Clinical Study Site
Istanbul, 34460, Turkey (Türkiye)
Clinical Study Site
Istanbul, 34722, Turkey (Türkiye)
Clinical Study Site
İzmit, 41380, Turkey (Türkiye)
Clinical Study Site
Konya, 42080, Turkey (Türkiye)
Clinical Study Site
Seyhan, 07059, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 3, 2025
First Posted
January 10, 2025
Study Start
February 27, 2025
Primary Completion (Estimated)
April 1, 2028
Study Completion (Estimated)
June 1, 2029
Last Updated
February 24, 2026
Record last verified: 2026-02